2013 American Transplant Congress
IL-1 Receptor Antagonist Treatment Rescues Impact of Brain Death Related Inflammation in Liver of Non-Human Primates
University of Wisconsin, Madison
Donor liver quality is critical to avoid primary non-function or dysfunction after transplantation. Previously, our lab developed a model of Non-human Primate (NHP) Brain death…2013 American Transplant Congress
MFI TRAP: HLAmatchmaker Can Help To Do the Reactions Patterns of DSA Versus NDSA To Assess Risk of Graft Failure by AMR, THE
The HLAMatchmaker (HLAMM) evaluates the compatibility between donor and recipient through comparisons within and between loci, and determines which epitopes in HLA mismatched are different…2013 American Transplant Congress
Activated T Regulatory Cells Escape Death by Increasing Cytoplasmic Serine Protease Inhibitor 6 (SPI6)
Medicine, Harvard Medical School, Boston
Regulatory T cells (Tregs) can employ a granzyme B (GrB)-dependent mechanism to mediate suppression of effector cells by inducing their apoptosis. Herein, we show that…2013 American Transplant Congress
Glomerular microRNA Expression Profiles in Transplant-Associated Thrombotic Microangiopathy
Thrombotic microangiopathy is a serious complication of renal transplantation. Besides recurrence of the primary disease (RecTMA) renal transplant-associated thrombotic microangiopathy (rTx-TMA) can emerge de novo…2013 American Transplant Congress
Low GFR after Kidney Donation Is Not Chronic Kidney Disease
Introduction:Living kidney donors have become of great importance to kidney transplantation. Obviously, living kidney donation is only justified if long-term donor safety is guaranteed. Many…2013 American Transplant Congress
Pregnancy Outcomes in Solid Organ Transplant Recipients with a Switch from a Mycophenolic Acid Product to Azathioprine Prior to Conception
The purpose of this study was to analyze pregnancy outcomes in female transplant recipients who switched their immunosuppressive regimen from a mycophenolic acid product (MPA)…2013 American Transplant Congress
Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Pharmacokinetics of the REFRESH Study
Background: REFRESH is a 2-part Phase 2b, open-label clinical study assessing safety, efficacy, and pharmacokinetics (PK) of telaprevir (T) in combination with peginterferon alfa-2a (P)…2013 American Transplant Congress
Anti-IL6R Suppresses Primary IgM Response and CD5+ B-1a Cell Subset Stimulated by HLA.A2+ Skin Allografts
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Background Inhibition of IL-6/IL-6R signaling using anti-IL6R monoclonal antibody is effective in attenuating donor-specific antibody (DSA) responses to skin allografts in a mouse model. Here,…2013 American Transplant Congress
Immune Suppressant Effect of Erythropoietin Alpha on Human Allo-Reactive T Cell Responses
Renal Division, Department of Medicine, Mount Sinai, New York
Recent clinical studies showed that complete correction of anemia with erythropoietin (EPO) therapy improves human kidney transplant outcomes, but mechanisms underlying this protective effect are…2013 American Transplant Congress
Defining pp65 Enemia and qPCR Cut-Offs for Pre-Emptive Therapy of CMV Disease in Low-Risk, Seropositive Renal Transplanted Recipients
Renal Transplant Service, University of São Paulo School of Medicine, Sao Paulo, Brazil
CMV disease mostly invasive gastro-intestinal with low viremia occurs in approximately 16% of CMV seropositive renal transplant recipients not receiving Thymoglobuline (ATG). Pre-emptive therapy (PETh)…
- « Previous Page
- 1
- …
- 142
- 143
- 144
- 145
- 146
- …
- 178
- Next Page »